All articles tagged with #verve 102
Two distinct experimental approaches are emerging to tackle high LDL cholesterol without daily medication. A CRISPR-based therapy, VERVE-102, showed a 62% reduction in bad cholesterol in a human trial, while a DNA-based molecule, HpE12, cut cholesterol by 47% in mice. Both target the PCSK9 protein, which regulates cholesterol clearance, offering potential alternatives to statins and current injectable inhibitors.
In a small Phase I study, Verve Therapeutics’ VERVE-102, a one-time mRNA-based gene-editing therapy targeting PCSK9, reduced LDL by up to 62% in the highest-dose group among 35 participants, with no serious safety events aside from a transient mild rise in a liver enzyme; results suggest durable LDL-C lowering, but larger and longer trials are needed for confirmation, and the FDA has granted Fast Track designation.
Eli Lilly’s high-dose, one-time gene-editing therapy VERVE-102 lowered LDL cholesterol by 62% in a Phase 1 trial, with no treatment-related serious adverse events, signaling potential for a single-shot approach to prevent heart disease after Lilly’s $1 billion acquisition of Verve Therapeutics.
An experimental gene therapy called VERVE-102, using base editing of the PCSK9 gene, shows promise in reducing LDL cholesterol in clinical trials, especially for those with familial hypercholesterolemia and premature coronary artery disease, with ongoing studies and potential for broad application.
A small clinical trial shows that a single infusion of the experimental gene-editing drug VERVE-102 can reduce LDL cholesterol levels by up to 69%, offering a potential permanent solution for high cholesterol through genetic modification, with further studies planned to confirm its safety and efficacy.